4th FCF Life Science Venture Capital Report published

The “4th FCF Life Science Venture Capital Report” addresses recent financing trends in the Life Science industry, investigating subsector activity, deal characteristics, cross-border and investor engagements in Europe and the US.

Key insights were:

  • Europe has continued its upward trend of life science venture financing in Europe, with UK recording the most transactions and highest volumes in the last 5 years
  • Oncology was the most sought indication in 2019, with BioNTech leading the TOP 10 deals in Europe
  • The biggest 2019 vintage funds were raised from British and French investors, pushing European venture capital fundraising volumes to the highest level in the last 5 years
  • Cross-border investors tend to play a more important role, especially in later stage rounds, with the US being the most important cross-border investor in Europe

To access the full report, please click here.